Placebo + Rusfertide
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera
Conditions
Polycythemia Vera
Trial Timeline
Apr 1, 2022 → Jun 1, 2027
NCT ID
NCT05210790About Placebo + Rusfertide
Placebo + Rusfertide is a phase 3 stage product being developed by Protagonist Therapeutics for Polycythemia Vera. The current trial status is active. This product is registered under clinical trial identifier NCT05210790. Target conditions include Polycythemia Vera.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05210790 | Phase 3 | Active |
Competing Products
20 competing products in Polycythemia Vera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 77 |
| ruxolitinib tablets | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| Ruxolitinib | Novartis | Phase 3 | 77 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 52 |
| Hydroxyurea | Novartis | Approved | 85 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 77 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 52 |
| PEGASYS + Aspirin | Roche | Phase 2 | 52 |
| RG7388 + Pegasys | Roche | Phase 1 | 33 |
| Idasanutlin | Roche | Phase 2 | 52 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 77 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 51 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 76 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 76 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 84 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 51 |